Background SIOP Ependymoma I was a non-randomised trial assessing event free and overall survival (EFS/OS) from non-metastatic intracranial ependymoma in children aged 3 to 21 years, treated with a staged management strategy. Chemotherapy efficacy in ependymoma is debated and therefore the response rate (RR) of subtotally resected (STR) ependymoma to vincristine, etoposide and cyclophosphamide (VEC) was an additional primary outcome. We report final results with 12-year follow-up and post hoc analyses of recently described biomarkers.

中文翻译：

---

SIOP 室管膜瘤 I：试验队列的最终结果、长期随访和分子分析：一项 BIOMECA 联盟研究

背景SIOP 室管膜瘤 I 是一项非随机试验，评估 3 至 21 岁儿童非转移性颅内室管膜瘤的无事件生存率和总生存率 (EFS/OS)，采用分阶段管理策略进行治疗。室管膜瘤的化疗疗效存在争议，因此次全切除 (STR) 室管膜瘤对长春新碱、依托泊苷和环磷酰胺 (VEC) 的反应率 (RR) 是另一个主要结果。我们报告了对最近描述的生物标志物进行12 年随访和事后分析的最终结果。